Thomas Brumby

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (<i>R</i>)‐<i>S</i>‐Cyclopropyl‐<i>S</i>‐(4‐{[4‐{[(1<i>R</i>,2<i>R</i>)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Ulrich Lücking, Rolf Jautelat, Martin Krüger et al. · ChemMedChem · 2013 · 173 citations

Aminopyrimidine Zk 304709, Lab Oddity Prevails, Lead Identification +21

Intra- and intermolecular hetero-Diels-Alder reactions. 17. Intramolecular hetero-Diels-Alder reaction of alkylidene- and benzylidenepyrazolones and benzylideneisoxazolones. Investigations toward the conformation of the transition state

Lutz F. Tietze, Thomas Brumby, M. PRETOR et al. · The Journal of Organic Chemistry · 1988 · 91 citations

Transition State, Engineering, Heterocyclic +13

Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2

Erik Eggert, R.C. Hillig, Silke Koehr et al. · Journal of Medicinal Chemistry · 2016 · 86 citations · Full text

Histone Modifications, Drug Target, Epigenetic Change +19

From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors

Rolf Jautelat, Thomas Brumby, Martina Schäfer et al. · ChemBioChem · 2005 · 81 citations · Full text

Pharmaceutical Science, Cancer Biology, Pharmaceutical Chemistry +17

Intra- and intermolecular hetero-Diels-Alder reactions. 45. Simple and induced diastereoselectivity in intramolecular hetero-Diels-Alder reactions of 1-oxa-1,3-butadienes. Experimental data and calculations

Lutz F. Tietze, Jens Fennen, Thomas Brumby et al. · The Journal of Organic Chemistry · 1994 · 60 citations

Chemical Engineering, Engineering, Heterocyclic +11